Evidence map›Paper›PMID 33621214›Full record

ArticleThe Journal of clinical investigation2021

SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.

Arturo Casadevall, Jeffrey P Henderson, Michael J Joyner, Liise-Anne Pirofski

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Exercise and Experiments of Nature.Comprehensive Physiology · 2023
    Article
  4. Review
  5. Article
  6. COVID-19 convalescent plasma therapy through the lens of the third year of the pandemic.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022
    Article
  12. Article
  13. Article
  14. Pharmaceuticals (Basel, Switzerland) · 2022
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?Drug design, development and therapy · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Arturo CasadevallDepartment of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Jeffrey P HendersonDepartments of Medicine and Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Michael J JoynerDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Liise-Anne PirofskiDepartments of Medicine and Microbiology and Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Albert Einstein College of Medicine · USJohns Hopkins University · USMayo Clinic · USWashington University in St. Louis · US

Funding

CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patientsUL1TR002556 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, KIM, MIMI Y · 2018 to 2022
$26.7M
Synergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4M
Biology of Fungal MelaninR01AI052733 · NIAID · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 2003 to 2019
$6.6M
Variant Hemoglobin and Cardiorespiratory Regulation in HumansR35HL139854 · NHLBI · MAYO CLINIC ROCHESTER · PI JOYNER, MICHAEL J · 2018 to 2024
$5.8M
Antibodies, B cells and resistance to human cryptococcosisR01AI143453 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI PIROFSKI, LIISE-ANNE · 2019 to 2024
$3.2M
Antibody therapy for pneumococcal diseaseR01AI123654 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PIROFSKI, LIISE-ANNE · 2017 to 2021
$2.1M
Metabolomic Mechanisms of Nutritional Immunity in the Urinary TractR01DK111930 · NIDDK · WASHINGTON UNIVERSITY · PI HENDERSON, JEFFREY P · 2018 to 2021
$1.4M
Metabolomic Mechanisms of Nutritional Immunity in the Urinary TractR56DK111930 · NIDDK · WASHINGTON UNIVERSITY · PI HENDERSON, JEFFREY P · 2016 to 2016
$125k
NCATS NIH HHS UL1 TR002556NHLBI NIH HHS R01 HL059842NHLBI NIH HHS R35 HL139854NIAID NIH HHS R01 AI052733NIAID NIH HHS R01 AI123654NIAID NIH HHS R01 AI143453NIDDK NIH HHS R01 DK111930NIDDK NIH HHS R56 DK111930
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 SerotherapyGenome, ViralHost Microbial InteractionsHumansImmune EvasionImmunization, PassiveModels, ImmunologicalPandemicsSARS-CoV-2Antibodies, NeutralizingAntibodies, Viral

Identifiers

PMID33621214
PMCPMC8011895
OpenAlexW3132147231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.